Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 9/2016

01-09-2016 | Original Article

Expression of mitochondrial genes MT-ND1, MT-ND6, MT-CYB, MT-COI, MT-ATP6, and 12S/MT-RNR1 in colorectal adenopolyps

Authors: LaShanale Wallace, Sharifeh Mehrabi, Methode Bacanamwo, Xuebiao Yao, Felix O. Aikhionbare

Published in: Tumor Biology | Issue 9/2016

Login to get access

Abstract

Despite improvements in treatment strategies, colorectal cancer (CRC) still has high mortality rates. Most CRCs develop from adenopolyps via the adenoma-carcinoma sequence. A mechanism for inhibition of this sequence in individuals with a high risk of developing CRC is urgently needed. Differential studies of mitochondrial (mt) gene expressions in the progressive stages of CRC with villous architecture are warranted to reveal early risk assessments and new targets for chemoprevention of the disease. In the present study, reverse transcription-quantitative PCR (RT-qPCR) was used to determine the relative amount of the transcripts of six mt genes [MT-RNR1, MT-ND1, MT-COI, MT-ATP6, MT-ND6, and MT-CYB (region 648–15887)] which are involved in the normal metabolism of mitochondria. A total of 42 pairs of tissue samples obtained from colorectal adenopolyps, adenocarcinomas, and their corresponding adjacent normal tissues were examined. Additionally, electron transport chain (ETC), complexes I (NADH: ubiquinone oxidoreductase) and III (CoQH2-cytochrome C reductase), and carbonyl protein group contents were analyzed. Results indicate that there were differential expressions of the six mt genes and elevated carbonyl protein contents among the colorectal adenopolyps compared to their paired adjacent normal tissues (p < 0.05). The levels of complexes I and III were higher in tumor tissues relative to adjacent normal tissues. Noticeably, the expression of MT-COI was overexpressed in late colorectal carcinomas among all studied transcripts. Our data suggest that increased expressions in certain mt genes and elevated levels of ROS may potentially play a critical role in the colorectal tumors evolving from adenopolyps to malignant lesions.
Literature
1.
Duarte FV, Palmeira CM, Rolo AP. The Role of microRNAs in mitochondria: small players acting wide. Genes (Basel). 2014;5:865–86.
2.
Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol Mech Dis. 2011;6:479–507.CrossRef
3.
Winawer SJ, Zauber AG, Ho MN, O’Brien MJ, Gottlieb LS, Sternberg SS, et al. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med. 1993;329:1977–81.CrossRefPubMed
4.
5.
Czarnecka A, Golik P, Bartnik E. Mitochondrial DNA mutations in human neoplasia. J Appl Genet. 2006;47:67–78.CrossRefPubMed
6.
Weren RDA, Ligtenberg MJL, Kets CM, de Voer RM, Verwiel ETP, Spruijt L, et al. A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. Nat Genet. 2015;47:668–71.CrossRefPubMed
7.
Bettington M, Walker N, Clouston A, Brown I, Leggett B, Whitehall V. The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology. 2013;62:367–86.CrossRefPubMed
8.
Adams G, Mehrabi S, Vatcharapijarn Y, Iyamu OI, Akwe JA, Grizzle WE, et al. Frequencies of mtDNA mutations in primary tissue of colorectal adenopolyps. Front Biosci (Elite Ed). 2013;5:809–13.
9.
Aikhionbare F, Khan M, Carey D, Okoli J, Go R. Is cumulative frequency of mitochondrial DNA variants a biomarker for colorectal tumor progression? Mol Cancer. 2004;3:30.CrossRefPubMedPubMedCentral
10.
Polyak K, Li Y, Zhu H, Lengauer C, Willson JKV, Markowitz SD, et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet. 1998;20:291–3.CrossRefPubMed
11.
12.
Mehrabi S, Partridge EE, Seffens W, Yao X, Aikhionbare FO. Oxidatively modified proteins in the serous subtype of ovarian carcinoma. Biomed Res Int. 2014;2014:585083.CrossRefPubMedPubMedCentral
13.
Chester KA, Robson L, Begent RHJ, Pringle H, Primrose L, Talbot IC, et al. In situ and slot hybridization analysis of RNA in colorectal tumours and normal colon shows distinct distributions of mitochondrial sequences. J Pathol. 1990;162:309–15.CrossRefPubMed
14.
Lee HC, Yin PH, Lin JC, Wu CC, Chen CY, Wu CW, et al. Mitochondrial Genome Instability and mtDNA Depletion in Human Cancers. Annals of the New York Academy of Sciences. 2005;1042:109–22.CrossRefPubMed
15.
Lu X, Walker T, MacManus JP, Seligy VL. Differentiation of HT-29 human colonic adenocarcinoma cells correlates with increased expression of mitochondrial RNA: effects of trehalose on cell growth and maturation. Cancer Research. 1992;52:3718–25.PubMed
16.
Yamamoto A, Horai S, Yuasa Y. Increased level of mitochondrial gene expression in polyps of familial polyposis coli patients. Biochemical and Biophysical Research Communications. 1989;159:1100–6.CrossRefPubMed
17.
Abril J, De Heredia ML, González L, Cléries R, Nadal M, Condom E, et al. Altered expression of 12S/MT-RNR1, MT-CO2/COX2, and MT-ATP6 mitochondrial genes in prostate cancer. Prostate. 2008;68:1086–96.CrossRefPubMed
18.
Evans P, Lyras L, Halliwell B. Measurement of protein carbonyls in human brain tissue. In: Methods in Enzymology Oxidants and Antioxidants Part B.Academic Press. 1999. p. 145–56.CrossRef
19.
Beal MF. Oxidatively modified proteins in aging and disease1,2. Free Radical Biology and Medicine. 2002;32:797–803.CrossRefPubMed
20.
Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, et al. Determination of carbonyl content in oxidatively modified proteins. In: Methods in enzymology oxygen radicals in biological systems part B: oxygen radicals and antioxidants. Academic Press. 1990. p. 464–78.CrossRef
21.
Bragoszewski P, Kupryjanczyk J, Bartnik E, Rachinger A, Ostrowski J. Limited clinical relevance of mitochondrial DNA mutation and gene expression analyses in ovarian cancer. BMC Cancer. 2008;8:292.CrossRefPubMedPubMedCentral
22.
Rubie C, Kempf K, Hans J, Su T, Tilton B, Georg T, et al. Housekeeping gene variability in normal and cancerous colorectal, pancreatic, esophageal, gastric and hepatic tissues. Molecular and Cellular Probes. 2005;19:101–9.CrossRefPubMed
23.
Andersen CL, Jensen JL, Ørntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Research. 2004;64:5245–50.CrossRefPubMed
24.
Mehrabi S, Wallace L, Cohen S, Yao X, Aikhionbare FO. Differential measurements of oxidatively modified proteins in colorectal adenopolyps. Int J Clin Med. 2015;6:288–99.CrossRefPubMedPubMedCentral
25.
26.
Grzybowska-Szatkowska L, Slaska B, Rzymowska J, Brzozowska A, Floriańczyk B. Novel mitochondrial mutations in the ATP6 and ATP8 genes in patients with breast cancer. Mol Med Rep. 2014;10:1772–8.PubMedPubMedCentral
27.
Sun AS, Cederbaum AI. Oxidoreductase activities in normal rat liver, tumor-bearing rat liver, and hepatoma HC-252. Cancer Research. 1980;40:4677–81.PubMed
28.
Chandra D, Singh KK. Genetic insights into OXPHOS defect and its role in cancer. Biochimica et Biophysica Acta (BBA) - Bioenergetics. 2011;1807:620–5.CrossRef
29.
Akouchekian M, Houshmand M, Akbari MHH, Kamalidehghan B, Dehghan M. Analysis of mitochondrial ND1 gene in human colorectal cancer. J Res Med Sci. 2011;16:50–5.PubMedPubMedCentral
30.
Rigoulet M, Yoboue ED, Devin A. Mitochondrial ROS generation and its regulation: mechanisms involved in H2O2 signaling. Antioxidants & Redox Signaling. 2010;14:459–68.CrossRef
31.
Zhang Y, Marcillat O, Giulivi C, Ernster L, Davies KJ. The oxidative inactivation of mitochondrial electron transport chain components and ATPase. Journal of Biological Chemistry. 1990;265:16330–6.PubMed
32.
Saybaşili H, Yϋksel M, Haklar G, Yalϛin AS. Effect of mitochondrial electron transport chain inhibitors on superoxide radical generation in rat hippocampal and striatal slices. Antioxid Redox Signal. 2001;3(6):1099–104.CrossRefPubMed
33.
Dasgupta S, Hoque MO, Upadhyay S, Sidransky D. Mitochondrial cytochrome B gene mutation promotes tumor growth in bladder cancer. Cancer Research. 2008;68:700–6.CrossRefPubMed
34.
Pelicano H, Zhang W, Liu J, Hammoudi N, Dai J, Xu RH, et al. Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential. Breast Cancer Research. 2014;16:434.CrossRefPubMedPubMedCentral
35.
Heerdt BG, Halsey HK, Lipkin M, Augenlicht LH. Expression of mitochondrial cytochrome c oxidase in human colonic cell differentiation, transformation, and risk for colonic cancer. Cancer Research. 1990;50:1596–600.PubMed
36.
Herrmann PC, Gillespie JW, Charboneau L, Bichsel VE, Paweletz CP, Calvert VS, et al. Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer. PROTEOMICS. 2003;3:1801–10.CrossRefPubMed
37.
Sun AS, Sepkowitz K, Geller SA. A study of some mitochondrial and peroxisomal enzymes in human colonic adenocarcinoma. Laboratory Investigation. 1981;44:13–7.PubMed
38.
Dmitrenko V, Shostak K, Boyko O, Khomenko O, Rozumenko V, Malisheva T, et al. Reduction of the transcription level of the mitochondrial genome in human glioblastoma. Cancer Letters. 2005;218:99–107.CrossRefPubMed
39.
Chandel NS, McClintock DS, Feliciano CE, Wood TM, Melendez JA, Rodriguez AM, et al. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1α during hypoxia: a mechanism of O2 sensing. Journal of Biological Chemistry. 2000;275(33):25130–8.CrossRefPubMed
40.
Oppenheimer SR, Mi D, Sanders ME, Caprioli RM. A Molecular Analysis of Tumor Margins by MALDI Mass Spectrometry in Renal Carcinoma. J Proteome Res. 2010;9:2182–90.CrossRefPubMedPubMedCentral
41.
Higuchi M. Roles of Mitochondrial DNA Changes on Cancer Initiation and Progression. Cell Biol (Henderson, NV). 2012;1:109.CrossRef
42.
Quinlan CL, Orr AL, Perevoshchikova IV, Treberg JR, Ackrell BA, Brand MD. Mitochondrial complex II can generate reactive oxygen species at high rates in both the forward and reverse reactions. J Biol Chem. 2012;287:27255–64.CrossRefPubMedPubMedCentral
43.
Musatov A, Robinson NC. Susceptibility of mitochondrial electron-transport complexes to oxidative damage. Focus on cytochrome c oxidase. Free Radical Research. 2012;46:1313–26.CrossRefPubMed
44.
Poyton RO, McEwen JE. Crosstalk between nuclear and mitochondrial genomes. Annu Rev Biochem. 1996;65:563–607.CrossRefPubMed
45.
Delsite R, Kachhap S, Anbazhagan R, Gabrielson E, Singh K. Nuclear genes involved in mitochondria-to-nucleus communication in breast cancer cells. Mol Cancer. 2002;1:1–10.CrossRef
46.
Baracca A, Chiaradonna F, Sgarbi G, Solaini G, Alberghina L, Lenaz G. Mitochondrial complex I decrease is responsible for bioenergetic dysfunction in K-ras transformed cells. Biochimica et Biophysica Acta (BBA) - Bioenergetics. 2010;1797:314–23.CrossRef
47.
48.
De Rasmo D, Panelli D, Sardanelli AM, Papa S. cAMP-dependent protein kinase regulates the mitochondrial import of the nuclear encoded NDUFS4 subunit of complex I. Cellular Signalling. 2008;20:989–97.CrossRefPubMed
49.
Puurand M, Peet N, Piirsoo A, Peetsalu M, Soplepmann J, Sirotkina M, et al. Deficiency of the complex I of the mitochondrial respiratory chain but improved adenylate control over succinate-dependent respiration are human gastric cancer-specific phenomena. Mol Cell Biochem. 2012;370:69–78.CrossRefPubMed
50.
Lim HY, Ho QS, Low J, Choolani M, Wong KP. Respiratory competent mitochondria in human ovarian and peritoneal cancer. Mitochondrion. 2011;11:437–43.CrossRefPubMed
51.
Simonnet H, Demont J, Pfeiffer K, Guenaneche L, Bouvier R, Brandt U, et al. Mitochondrial complex I is deficient in renal oncocytomas. Carcinogenesis. 2003;24:1461–6.CrossRefPubMed
52.
Bonora E, Porcelli AM, Gasparre G, Biondi A, Ghelli A, Carelli V, et al. Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial dna mutations affecting complexes I and III. Cancer Research. 2006;66:6087–96.CrossRefPubMed
53.
Chandran UR, Dhir R, Ma C, Michalopoulos G, Becich M, Gilbertson J. Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer. 2005;5:1–11.CrossRef
54.
Prakash K, Pirozzi G, Elashoff M, Munger W, Waga I, Dhir R, et al. Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proceedings of the National Academy of Sciences. 2002;99:7598–603.CrossRef
55.
Metadata
Title
Expression of mitochondrial genes MT-ND1, MT-ND6, MT-CYB, MT-COI, MT-ATP6, and 12S/MT-RNR1 in colorectal adenopolyps
Authors
LaShanale Wallace
Sharifeh Mehrabi
Methode Bacanamwo
Xuebiao Yao
Felix O. Aikhionbare
Publication date
01-09-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5101-3

Other articles of this Issue 9/2016

Tumor Biology 9/2016 Go to the issue

Original Article

Rac3 regulates cell proliferation through cell cycle pathway and predicts prognosis in lung adenocarcinoma

Original Article

TUSC3 suppresses glioblastoma development by inhibiting Akt signaling

Original Article

Genetic polymorphism of HLA-DQ confers susceptibility to hepatitis B virus-related hepatocellular carcinoma: a case-control study in Han population in China

Original Article

Yeast two-hybrid screening identified WDR77 as a novel interacting partner of TSC22D2

Original Article

CYLD downregulates Livin and synergistically improves gemcitabine chemosensitivity and decreases migratory/invasive potential in bladder cancer: the effect is autophagy-associated

Original Article

S100A16 promotes cell proliferation and metastasis via AKT and ERK cell signaling pathways in human prostate cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits